LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Inicio・Lista de Acciones・Innoviva Inc

Innoviva Inc

Cerrado

SectorSanidad

21.35 -2.24

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

21.25

Máximo

21.45

Métricas clave
By Trading Economics
Ingresos	-55M 187M
Ventas	-20M 98M
P/B Media del Sector	3.588 50.102
BPA	0.47
Margen de beneficios	190.415
Empleados	159
EBITDA	-160M 48M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+61.06% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-45M 1.7B
Apertura anterior	23.59
Cierre anterior	21.35

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

75 / 344 Clasificación en Healthcare

Innoviva Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

29 may 2026, 23:08 UTC

Adquisiciones, fusiones, absorciones

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 may 2026, 23:06 UTC

Adquisiciones, fusiones, absorciones

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 may 2026, 20:53 UTC

Ganancias

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 may 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

29 may 2026, 20:33 UTC

Charlas de Mercado

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 may 2026, 20:11 UTC

Ganancias

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 may 2026, 19:47 UTC

Ganancias

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 may 2026, 19:36 UTC

Charlas de Mercado

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 may 2026, 19:34 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

29 may 2026, 19:34 UTC

Charlas de Mercado

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 may 2026, 19:22 UTC

Charlas de Mercado

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 may 2026, 19:05 UTC

Adquisiciones, fusiones, absorciones

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 may 2026, 18:19 UTC

Charlas de Mercado

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 may 2026, 18:12 UTC

Adquisiciones, fusiones, absorciones

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 may 2026, 18:11 UTC

Charlas de Mercado

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 may 2026, 18:10 UTC

Charlas de Mercado

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 may 2026, 17:55 UTC

Ganancias

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 may 2026, 17:55 UTC

Charlas de Mercado

NEAR Protocol Nearly Doubles in May -- Market Talk

29 may 2026, 17:38 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 may 2026, 17:00 UTC

Ganancias

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 may 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

29 may 2026, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

29 may 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

29 may 2026, 16:02 UTC

Charlas de Mercado

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 may 2026, 15:55 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

29 may 2026, 15:55 UTC

Charlas de Mercado

Cryptocurrencies Appear Detached From Stocks -- Market Talk

29 may 2026, 15:50 UTC

Adquisiciones, fusiones, absorciones

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

29 may 2026, 15:50 UTC

Adquisiciones, fusiones, absorciones

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

29 may 2026, 15:40 UTC

Charlas de Mercado

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

29 may 2026, 15:20 UTC

Charlas de Mercado

Canada's Economy Not Looking All That Bright -- Market Talk

Comparación entre iguales

Cambio de precio

Innoviva Inc previsión

Precio Objetivo

By TipRanks

61.06% repunte

Estimación a 12 Meses

Media 34.5 USD 61.06%

Máximo 46 USD

Mínimo 18 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Innoviva Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

Comprar

Mantener

Vender

De acuerdo con 4 analistas que ofrecen calificaciones bursátiles a para Innoviva Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

75 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.